實驗要點及說明：

1．本方法適用于貼壁細(xì)胞培養(yǎng)，而不適用于懸浮細(xì)胞培養(yǎng)，懸浮細(xì)胞可使用滴片法； 

2．所使用的蓋玻片應(yīng)該為玻璃**，并經(jīng)過鉻酸洗液處理； 

3．蓋玻片非常薄，易碎，取放蓋玻片時動作要輕； 

4．如果需要更多生長狀態(tài)一致的細(xì)胞，可以使用較大的培養(yǎng)皿，但不宜過大，以避免培養(yǎng)液的浪費(fèi)和增加污染機(jī)率； 

5．如果細(xì)胞貼壁生長能力較差，可將蓋玻片在0.5%多聚賴氨酸溶液中浸泡5-10分鐘并自然晾干。

培養(yǎng)方法

傳代方法 將舊培養(yǎng)液吸除，PBS清洗兩遍后，加入6mL（/100mm皿）胰酶，在顯微鏡下觀察，期間禁止搖晃培養(yǎng)皿，細(xì)胞剛有脫落時，則吸除大部分胰酶，留約0.5mL，移至培養(yǎng)箱消化，約2min取出。傳代用12mL CM1-1培養(yǎng)液終止消化，輕輕吹打均勻細(xì)胞，后可分3~6皿培養(yǎng)；

生長條件 37℃，5%CO2，CM1-1培養(yǎng)液。CM1-1培養(yǎng)液：90%DMEM-H+10%FBS。DMEM-H：DMEM高糖培養(yǎng)液，含谷氨酰胺，含丙酮酸鈉。

存儲條件 凍存則用6mL凍存液（90%FBS+10%DMSO）終止消化，吹打均勻，分為6支凍存管???用程序降溫盒于-80℃凍存，過夜轉(zhuǎn)移至液氮中保存。

我司常期代理ATCC Acris  abcam  cst  Biorbyt  santa  Novus  sigma  lifespan  NEB  roche  ABI  R&D millipore   BD  Qiagen Cayman  Jackson Life  GeneTex   Bio-Rad DSHB  tocris   peprotech 等品牌；部分產(chǎn)品現(xiàn)貨，超低比價，貨期短，價格優(yōu)，公司產(chǎn)品僅用于科研售后齊全。

培養(yǎng)操作步驟 ：

1．用蓋片鑷將蓋玻片自75%乙醇中取出，用無菌絲綢布擦拭干凈，不要用紗布； 

2．將蓋玻片輕輕放入6孔培養(yǎng)板（每孔一片）或培養(yǎng)皿中（每個平皿可放置2-3片）； 

3．在距離紫外燈直射范圍內(nèi)20-30 厘米處照射2-3小時； 

4．將經(jīng)過計數(shù)的細(xì)胞懸浮液移入培養(yǎng)板中，使蓋玻片完全浸在培養(yǎng)液中； 

5．將培養(yǎng)板在5% CO2水浴孵箱中37℃孵育2-3天，當(dāng)貼壁細(xì)胞生長至覆蓋培養(yǎng)板底部2/3面積時，將培養(yǎng)板取出，用蓋片鑷輕輕取出蓋玻片，用蒸餾水漂洗后即可進(jìn)行快速固定以及細(xì)胞化學(xué)檢測。 

細(xì)胞培養(yǎng)方法：

1、細(xì)胞傳代：細(xì)胞密度達(dá)到80-90%時即可傳代

①棄去培養(yǎng)上清，用PBS或生理鹽水清洗1-2次；

②加入2ml0.25%胰酶（T25瓶），使胰酶覆蓋整個瓶或皿，蓋好放入培養(yǎng)箱消化；

③1-2min后，顯微鏡下觀察細(xì)胞，若大部分細(xì)胞回縮且有少量細(xì)胞脫落，輕輕吹打下確認(rèn)消化情況后加入完全培養(yǎng)基終止消化；若細(xì)胞還是貼壁，放回培養(yǎng)箱繼續(xù)消化至可以輕輕吹打下為止；

④將細(xì)胞懸液1000RPM左右條件下離心4min，棄上清；

⑤用新鮮培養(yǎng)基重懸后加入培養(yǎng)瓶或皿中，T25培養(yǎng)瓶加6-8ml培養(yǎng)基；

⑥懸浮細(xì)胞直接離心收集，細(xì)胞沉淀重懸后分到新培養(yǎng)瓶中。

2、細(xì)胞復(fù)蘇：

①將凍存管在37℃溫水中快速搖晃融化，時間1min左右，加入4-5ml培養(yǎng)基混勻。

②在1000RPM左右條件下離心4min，棄上清,加1-2ml培養(yǎng)基吹勻，將細(xì)胞懸液加入培養(yǎng)瓶中，補(bǔ)加適量培養(yǎng)基。

3、細(xì)胞凍存：待細(xì)胞生長狀態(tài)良好時進(jìn)行細(xì)胞凍存保種

①棄去培養(yǎng)上清，用PBS或生理鹽水清洗1-2次，加入1mL 0.25%胰蛋白酶（T25瓶）

②1-2min后，顯微鏡下觀察細(xì)胞，大部分細(xì)胞回縮且有少量細(xì)胞脫落，輕輕吹打下確認(rèn)消化情況后加入完全培養(yǎng)基終止消化；

③將細(xì)胞懸液1000RPM左右條件下離心4min，棄上清，加1ml凍存液重懸細(xì)胞；

④將凍存管放入程序降溫盒，放入-80℃冰箱，4小時后將凍存管轉(zhuǎn)入液氮罐儲存。

Function : Binds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling.

Subunit : Heterodimer of a regulatory subunit PIK3R1 and a p110 catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts with FER. Interacts (via SH2 domain) with TEK/TIE2 (tyrosine phosphorylated). Interacts with PTK2/FAK1. Interacts with phosphorylated TOM1L1. Interacts with phosphorylated LIME1 upon TCR and/or BCR activation. Interacts with SOCS7. Interacts with RUFY3. Interacts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with LYN (via SH3 domain); this enhances enzyme activity. Interacts with phosphorylated LAT, LAX1 and TRAT1 upon TCR activation. Interacts with CBLB. Interacts with HIV-1 Nef to activate the Nef associated p21-activated kinase (PAK). This interaction depends on the C-terminus of both proteins and leads to increased production of HIV. Interacts with HCV NS5A. The SH2 domains interact with the YTHM motif of phosphorylated INSR in vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and CD3Z upon T-cell activation. Interacts with IRS1 and phosphorylated IRS4, as well as with NISCH and HCST. Interacts with FASLG, KIT and BCR. Interacts with AXL, FGFR1, FGFR2, FGFR3 and FGFR4 (phosphorylated). Interacts with FGR and HCK. Interacts with PDGFRA (tyrosine phosphorylated) and PDGFRB (tyrosine phosphorylated). Interacts with ERBB4 (phosphorylated). Interacts with NTRK1 (phosphorylated upon ligand-binding).

Tissue Specificity : Isoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level).

Post-translational modifications : Polyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation.

Phosphorylated. Tyrosine phosphorylated in response to signaling by FGFR1, FGFR2, FGFR3 and FGFR4. Phosphorylated by CSF1R. Phosphorylated by ERBB4. Phosphorylated on tyrosine residues by TEK/TIE2. Dephosphorylated by PTPRJ. Phosphorylated by PIK3CA at Ser-608; phosphorylation is stimulated by insulin and PDGF. The relevance of phosphorylation by PIK3CA is however unclear. Phosphorylated in response to KIT and KITLG/SCF. Phosphorylated by FGR.

Similarity : Belongs to the PI3K p85 subunit family.

Contains 1 Rho-GAP domain.

Contains 2 SH2 domains.

Contains 1 SH3 domain.

英文名稱  Anti-phospho-PIK3R1(Tyr556)

中文名稱  磷酸化磷脂酰肌醇激酶抗體

別    名  PIK3R1(phospho Y556); GRB1; p50 alpha; p55 alpha; p85 alpha; p85; Phosphatidylinositol 3 kinase associated p85 alpha; Phosphatidylinositol 3 kinase regulatory 1; Phosphatidylinositol 3 kinase regulatory alpha subunit; Phosphoinositide 3 kinase regulatory subunit polypeptide 1 (p85 alpha); PI3 kinase p85 alpha subunit; PI3 kinase p85 subunit alpha; PI3K ; PIK3R1; PtdIns 3 kinase p85 alpha.

濃    度  1mg/1ml

規(guī) 格  0.1ml/100μg

抗體來源  Rabbit  

克隆類型  polyclonal

交叉反應(yīng)  Human, Mouse, Rat, Dog, Pig, Cow, Horse, Rabbit, Guinea Pig

產(chǎn)品類型  一抗  磷酸化抗體   
肝成纖維細(xì)胞腫瘤壞死因子α檢測試劑盒氟化，無水 SP氯亞鈀酸銨 Pd ≥36.5%

腫瘤壞死因子α誘導(dǎo)蛋白6檢測試劑盒氟化，無水 99.9% metals basis氯銥酸銨 銥含量：43.0%

腫瘤壞死因子α轉(zhuǎn)化酶檢測試劑盒氟化，無水 AR，顆粒氧化金 金含量≥88.6 %

腫瘤壞死因子β檢測試劑盒氟化，無水 電子級，粉末反式-雙(三苯基膦)合氯化羰基銠(Ⅰ) Rh 14.91%

腫瘤壞死因子γ檢測試劑盒13-乙酰基-9-羥基巴卡丁III 分析標(biāo)準(zhǔn)品，≥99%雙(苯)二氯鉑(II) Pt ≥41.0%

腫瘤壞死因子可溶性受體Ⅰ檢測試劑盒13-乙?；?9-羥基巴卡丁III 99%二氯二氨鈀 Pd ≥50%

腫瘤壞死因子可溶性受體Ⅱ檢測試劑盒10-脫乙酰基巴卡丁 III 95%氯銥酸 Ir 35% in HCl